Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04176198 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
A Phase 1 study of Myelofibrosis, sponsored by Sumitomo Pharma America.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT04176198 is a Phase 1 study of Myelofibrosis that is actively recruiting participants, run by Sumitomo Pharma America. The registered enrollment target is 240 participants, above the 192-participant average among 61 other Myelofibrosis trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT04176198, a Phase 1 study of Myelofibrosis, is actively recruiting participants, sponsored by Sumitomo Pharma America.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Conditions Studied
Interventions
- DRUG Nusivertib
- DRUG Ruxolitinib
- DRUG Momelotinib
Study Locations (20)
California
- City of Hope - Duarte
- University of Southern California - Los Angeles
- Hoag Family Cancer Institute - Newport Beach
Florida
- University of Florida Health Shands Cancer Hospital - Gainesville
- University of Miami - Miami
- Baptist Health - Miami Cancer Institute - Miami
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Icahn School of Medicine at Mount Sinai - New York
Alabama
- University of Alabama - Birmingham
Arizona
- The University of Arizona Cancer Center - Tucson
Colorado
- Blood Cancer Center - Denver
Connecticut
- Yale School of Medicine - New Haven
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2019-12-16 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04176198
The ClinicalTrials.gov registry entry for NCT04176198 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 61 other Myelofibrosis trials with a reported enrollment target (25% higher). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 3 interventions - of which Nusivertib is the first listed.
NCT04176198 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04176198 about?
NCT04176198 is a clinical study titled "A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis". This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
What is the current status of trial NCT04176198?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2019-12-16. Estimated completion is 2030-04-30.
What conditions does trial NCT04176198 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT04176198?
The interventions under investigation include: Nusivertib (DRUG), Ruxolitinib (DRUG), Momelotinib (DRUG).
Who is sponsoring clinical trial NCT04176198?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04176198 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
-
A Safety and Tolerability Study of Jaktinib
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.